Drugs / eliapixant
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT04802343 | Apr → Jul 2021 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04471337 | Aug 2020 → Feb 2021 | diabetic neuropathy, endometriosis, overactive bladder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04487431 | Aug → Sep 2020 | diabetic neuropathy, endometriosis, overactive bladder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04454424 | Jul 2020 → Jun 2021 | diabetic neuropathy, endometriosis, overactive bladder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04423744 | Jun → Nov 2020 | endometriosis, overactive bladder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04252300 | Mar → Aug 2020 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04265781 | Feb → Sep 2020 | diabetic neuropathy, endometriosis, overactive bladder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03773068 | Dec 2018 → Jun 2019 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02817100 | Jul 2016 → May 2017 | — | Bayer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03310645 | Dec 2017 → May 2019 | — | Bayer | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04614246 | Jan 2021 → Jan 2022 | endometriosis | Bayer | Terminated | No outcome recorded |
| Phase 2 | NCT04641273 | Jan → Sep 2021 | diabetic polyneuropathy | Bayer | Terminated | No outcome recorded |
| Phase 2 | NCT04562155 | Oct 2020 → Jun 2021 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT04545580 | Sep 2020 → Dec 2021 | overactive bladder | Bayer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eliapixant | “The potent, selective P2X3 receptor antagonist eliapixant (BAY 1817080) is under development for conditions characterized by neuronal hypersensitization.” PMID 36469250 ↗ Dec 20224“Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.” PMID 33986030 ↗ Nov 2021 “Selectivity of the P2X3 receptor antagonist Eliapixant, and its potential use in the treatment of endometriosis.” PMID 34978027 ↗ Jan 2022 “Eliapixant, a selective P2X3 receptor antagonist, has been in clinical development for all four disorders.” PMID 38907175 ↗ Jun 2024 “Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.” PMID 38044419 ↗ Dec 2023 |
| Known as | BAY 1817080 | “Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.” PMID 33986030 ↗ Nov 2021 |
| Action | Inhibit | “selective P2X3 receptor antagonist” PMID 38044419 ↗ Dec 2023 |
| Modality | Small molecule | — CHEMBL5095224 ↗ |
| Route | Oral | “increasing single oral doses (10 - 1500 mg, Tablets) of BAY1817080” NCT02817100 ↗ |
| Target | P2RX3 | “P2X3 receptor antagonist Eliapixant” PMID 34978027 ↗ Jan 2022 |